| B33 | Long-term (96-week) safety of fostemsavir (FTR) in heavily treatment-experienced (HTE) adults infected with multidrug-resistant (MDR) HIV-1 (BRIGHTE Phase 3 study) | E-poster | ART in highly treatment-experienced people |
| B33 | Weight changes in HIV+ individuals receiving ibalizumab over 96 weeks | E-poster | ART in highly treatment-experienced people |
| B33 | Clinical impact of antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analyses of the phase 3 BRIGHTE study | E-poster | ART in highly treatment-experienced people |
| B33 | Aggregating loss to follow-up behavior in Patients Living with HIV: a cluster analysis using unsupervised machine learning algorithm in R | E-poster | ART in highly treatment-experienced people |
| B32 | Integrase strand transfer inhibitor (INSTI) use and cancer incidence | E-poster | ART in first- and second-line therapies |
| B32 | Antiretroviral therapy for HIV controllers: indications and outcomes in the French ANRS-CO21 CODEX cohort | E-poster | ART in first- and second-line therapies |
| B32 | Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine? | E-poster | ART in first- and second-line therapies |
| B32 | High rates of viral suppression sixteen weeks after transition from EFV- to DTG-based ART regardless of viral load at transition: the DO-REAL cohort study in Lesotho | E-poster | ART in first- and second-line therapies |
| B32 | The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: results from the DRIVE-AHEAD clinical trial | E-poster | ART in first- and second-line therapies |
| B32 | Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in treatment-experienced HIV-1 infected patients: week 48 analysis from the randomized controlled phase 3 TALENT study | E-poster | ART in first- and second-line therapies |